Polycystic ovary syndrome (PCOS) is a common endocrine disorder affecting women of reproductive age. It is characterized by a variety of symptoms, including irregular menstrual cycles, infertility, obesity, hirsutism, acne, and insulin resistance. PCOS is a complex disorder, and its pathogenesis remains largely unknown. Despite its prevalence, PCOS is often underdiagnosed or misdiagnosed due to the lack of a clear diagnostic criteria. This article aims to provide an overview of PCOS and its management, in order to help physicians better recognize and treat the disorder.
PCOS is a heterogeneous disorder with variable presentations. It is characterized by anovulation, hyperandrogenism, and polycystic ovarian morphology. Anovulation is defined as the absence of ovulation, and is the most common symptom of PCOS. Hyperandrogenism is the presence of elevated androgens, such as testosterone, in the blood. Polycystic ovarian morphology is the presence of multiple small cysts in the ovaries, which can be seen on ultrasound.
The diagnosis of PCOS is based on the presence of two of the three criteria: anovulation, hyperandrogenism, and polycystic ovarian morphology. Anovulation can be diagnosed by a history of irregular menstrual cycles, or by monitoring for ovulation with basal body temperature or urinary luteinizing hormone (LH) tests. Hyperandrogenism can be diagnosed by measuring serum testosterone and other androgens. Polycystic ovarian morphology can be diagnosed by transvaginal ultrasound.
PCOS is associated with a number of complications, including infertility, obesity, hirsutism, acne, and insulin resistance. Infertility is the most common complication of PCOS, and is caused by the lack of ovulation. Obesity is also common in PCOS, and is thought to be due to insulin resistance. Hirsutism, acne, and insulin resistance can also be caused by the elevated androgens associated with PCOS.
The management of PCOS depends on the patient's individual presentation and goals. For those with fertility issues, ovulation induction with drugs such as clomiphene citrate or gonadotropins may be recommended. For those with hirsutism, acne, or obesity, lifestyle modifications such as diet and exercise as well as medications such as metformin or spironolactone may be recommended.
PCOS is a complex disorder that affects many women of reproductive age. It is characterized by anovulation, hyperandrogenism, and polycystic ovarian morphology, and is associated with a number of complications, including infertility, obesity, hirsutism, acne, and insulin resistance. The diagnosis of PCOS is based on the presence of two of the three criteria, and the management of PCOS depends on the patient's individual presentation and goals. With a better understanding of PCOS and its management, physicians can help women better recognize and treat the disorder.
1.
Le cancer et le COVID ont conduit le patient à une double transplantation de poumon.
2.
Effective for localizing small, non-palpable breast lesions is ultrasound-guided localization with magnetic seeds.
3.
Long-term study links chronic conditions in midlife to higher cancer risk and mortality
4.
Subcutaneous Cancer Immunotherapies Provide New Options for Physicians and Patients
5.
When does a melanoma metastasize? Implications for management
1.
Unlocking the Mysteries of Reticulocyte Counts: A Guide to Understanding Your Blood Results
2.
The Checkpoint Architect: Unraveling the Mechanisms of PD-L1 Regulation for the Next Generation of Small-Molecule Therapies
3.
Screening Efficacy, Molecular Precision, and Therapeutic Revolutions in Lung Cancer 2025
4.
Genetic Testing in Cancer Prevention: BRCA Mutations and Lynch Syndrome Unlocked
5.
Transforming Cancer Care: CAR T-Cell Therapy for Relapsed/Refractory NHL and ALL
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
3.
An In-Depth Look At The Signs And Symptoms Of Lymphoma
4.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part IV
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation